Dual blockade angiotensin-receptor neprilysin-inhibitor (ARNI) -
A new era for heart failure treatment

Oana Tautu *, Maria Manea, Maria Dorobantu

Carol Davila University of Medicine and Pharmacy, Cardiology Department,
Clinical Emergency Hospital, Bucharest, Romania

Received: October 17, 2017, Accepted: December 11, 2017

Abstract

Blockade of neurohormonal over-activation through beta-blockers, angiotensin – converting enzyme inhibitors (ACEIs), angiotensin-receptor blockers (ARBs) and mineralocorticoid-receptor antagonists (MRA) represents the core-stone of the medical treatment in chronic heart failure. Since their use into the daily clinical practice recommended by the guidelines, the overall survival of heart failure patients has significantly increased. But yet, there is still room for improvement, since on the long term these patients remain at an increased risk of acute worsening episodes requiring hospitalization and mortality. This „residual” morbimortality could be explained by a persistent inadequate response of the endogenous adaptive mechanisms in chronic heart failure that is not target by sympathetic nervous system (SNS) – renin angiotensin aldosterone system (RAAS) inhibition strategy. The dual angiotensin-receptor neprilysin – inhibitor has proven a superior efficacy in decreasing the morbimortality of chronic heart failure patients that the standard of care treatment, and is widely recommended by all the guidelines for treatment in patients with heart failure with reduced ejection fraction, being the first heart failure drug that gets into the guidelines after the completion of only one (but the largest) clinical trial. Also there are several issues that await a response regarding the use of ARNI as first-line treatment instead of ACEIS and ARBs, that for sure will come in the next years, we can neither the less say that ARNI sacubitril-valsartan has the traits of a revolutionary drug that has definitely changed the paradigm of the HF treatment.

Keywords: heart failure, ARNI, neprilysin inhibitor, ARB, valsartan, LCZ696, sacubitril

* Correspondence to: Oana TAUTU, MD, PhD
Clinical Emergency Hospital Bucharest, Calea Floreasca no.8, sector 1, postal code 014461, Bucharest, Romania.
Tel./fax: 004021-3170108; e-mail: dr.tautu@yahoo.com

©The Author(s) 2017. This article is published with open access under the terms of the Creative Commons Attribution License.
could be explained by a persistent inadequate response of the endogenous adaptive mechanisms in chronic heart failure that is not target by sympathetic nervous system (SNS) – renin angiotensin aldosterone system (RAAS) inhibition strategy.

Natriuretic peptides system, bradykinin or adrenomedulin are peptides produced to suppress the negative effects of RAAS and SNS, promoting vasodilation and natriuresis, inhibit the abnormal growth and cardiac and vascular remodelling [1]. Their effects include, also, increase of the glomerular filtration, renin and aldosterone inhibition and they have, also, antihypertrophic and antifibrotic actions, vascular regeneration, arterial and venodilatation [2].

The natriuretic peptide system consists of atrial natriuretic peptide (ANP) that is secreted in response to atrial dilation, B-type natriuretic peptide (BNP), secreted in response to the increased ventricle wall stress and C-type (CNP) which is derived from endothelial and renal cells[3]. CNP and BNP are released in response to increased stress of the cardiac wall in the context of volume or pressure overload. Their levels are higher in patients with heart failure [4].

Since natriuretic peptide have the potential of counteracting the overstimulation of SNS and RAAS, when their plasmatic circulation levels are increased secondary to volume-pressure overload they should balance and prevent the decompensation episode. But this does not happen in real life. In fact, levels of BNP and NT-proBNP are well known markers used for detecting episodes of decompensations in heart failure: the higher the BNP/ NT-proBNP levels the worst the episode. And why these increased levels of natriuretic peptides fail to prevent the acute episode in a heart failure patient? The response comes for studies on mass spectrometry and measurements of circulating natriuretic peptides that proved that in patients with acute decompensating episodes, the increased plasmatic levels of natriuretic peptides are in fact of increased levels of inactive fragments of natriuretic peptides that do no longer have the same beneficial biological effects on SNS/RAAS as the mature peptides.

Increasing the natriuretic peptides circulating levels is therefore considered an optimal strategy in the treatment for heart failure [5,6]. So far, oral administration of these peptide has been proven to be ineffective, so the option to increase natriuretic peptides is to develop an alternative approach.

Nepriysine (NEP) is a metallopeptidase enzymes which brake-down the natriuretic peptides into inactive circulating fragments.

Having an optimal endogen counteracting natriuretic peptide system could be the necessary step for eliminating the residual mortality in heart-failure patients. And for that is required not only the increase in circulating levels of natriuretic peptides but also to protect them from inactivation by the use of nepriysin inhibitors. Never the less, keeping in mind that, besides inactivation of natriuretic peptides, nepriysin also inhibits several other peptides such as bradykinin, endothelin, angiotensin I and II, the use of an nepriysin inhibitor will result in a supplementary activation of RAAS, an agent who blocks simultaneously neutral endopeptidase and RASS is necessary [1].

**Neprilisyn inhibitor. From Candoxatril to sacubitril/valsartan**

Candoxatril was the first neutral endopeptidase inhibitor, but this drug could not adjust the blood pressure in hypertensive patients and vascular resistances in patients with heart failure [6].

Omapatrilat was the first inhibitor of neutral endopeptidase and the angiotensin-converting enzyme, with a better profile than candoxatril regarding the blood pressure and the vascular resistances, but his use was stopped because of a high risk of angioedema [7].

Angiotensin receptor nepriysin inhibitors (ARNI) is a new class of heart failure drug whose effect is to block RAAS and increase the natriuretic peptides [3, 8].

The US Food and Drug administration (FDA) approved on July 2015 sacubitril/valsartan to reduce the risk of death and hospitalization in patients diagnosed with heart failure, NYHA class II-IV and associated with reduced ejection fraction.

Sacubitril/valsartan is a combination of angiotensin receptor neutral endopeptidase inhibitor (ARNI) with the angiotensin II receptor antagonist valsartan. Angiotensin receptor nepriysin inhibitor is a new class of drug used to block the RAAS and increase natriuretic peptides [9,10]. So, sacubitril has the potential to reduce the negative effects of the neurohormonal activity in heart failure.
**Sacubitril/valsartan: Mechanism of action**

Sacubitril is a neutral endopeptidase inhibitor (a nephrilysin inhibitor). Valsartan is an angiotensin receptor blocker. LCZ696 (sacubitril/valsartan) is the main one in his category of ARNI [1].

After oral administration of the sacubitril/valsartan, the drug dissociates into valsartan, an ARB, and AHU377, which is nephrilysin inhibitor prodrug which is further metabolised to LBQ657, this being the active form. LCZ696 increases plasma and urinary levels of cGMP, by activating the NPR-A receptor and, also, blocks the angiotensin type I receptor [9,10].

The peak levels of those two drugs are reached at the same time. The steady-state of valsartan and sacubitril (LBQ657) appears in 3 days [9]. So, the combination between sacubitril (LBQ657 active metabolite of sacubitril) and valsartan inhibits nephrilysin (neutral endopeptidase) via LBQ657 and is associated with blockade of angiotensin II type I receptor via valsartan. Valsartan selectively blocks the angiotensin I receptor, so it inhibits the angiotensin II effects. Also, valsartan inhibits the aldosterone release.

The effects of sacubitril/valsartan are the consequences of NEP and RAAS inhibition. The effects of sacubitril/valsartan were evaluated in a 7 day controlled study in which were noted an increase in natriuresis and the increased levels of cGMP in urine [8]. Also, in a 21 day study, the levels of cGMP in plasma and urine were high[20]. In PARAMOUNT study, a phase II, randomised, double-blind trial (were included patients with NYHA II-III, with left ventricular ejection fraction over 45% and with NT-proBNP levels over 400 pg/m), the levels of NT-proBNP were reduced after administration of sacubitril/valsartan [11].

**Dosing and administration**

The recommended dose at initiation of treatment is 49 mg sacubitril with 51 mg of valsartan twice daily [12], the dose being doubled after 2 weeks. A 24 mg sacubitril with 26 mg valsartan starting dose is recommended for patients who are not receiving ACEI or an angiotensin receptor blocker and, also, for patients with renal or hepatic dysfunction [3].

The combination of sacubitril/valsartan is available in tablets with the following concentrations: 24 mg of sacubitril and 26 mg valsartan, 49 mg of sacubitril and 51 mg valsartan, 97 mg sacubitril and 103 mg valsartan [13].

**Adverse effects and contraindications**

Hypotension is the most frequently encountered adverse effect of administration sacubitril/valsartan, with an incidence over 5%. Also, most common adverse effects are hyperkalaemia, cough, dizziness and renal failure (for patients who were already with renal dysfunction) [14].

This drug is contraindicated for patients with history of angioedema at previous administration of an ACEI. It is also contraindicated to use this drug in combination with an ACEI or an angiotensin receptor blocker, because valsartan is an angiotensin receptor blocker, with cumulative side effects [11]. Also, concomitant administration of sacubitril/valsartan with potassium-sparing diuretics or potassium supplements [13]. The concomitant use of sacubitril/valsartan with nonsteroidal anti-inflammatory drugs can lead to worsening the renal function in patients with renal dysfunction, elderly [15].

The combination of valsartan with sacubitril should be administered with precaution in patients with history of angioedema, hypotension, impaired renal function or hyperkalaemia. Also, the use of this drug should be discontinued when pregnancy is detected because can be toxic for the foetus [12].

**Sacubitril/valsartan in clinical trials**

PARADIGM-HF (The Prospective Comparison of ARNI with ACE inhibitors to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) is a randomised, double-blind and event-driven trial whose purpose was to compare the effects of sacubitril/valsartan and enalapril in patients diagnosed with chronic and symptomatic heart failure. This study started in December 2004 and was stopped in March 2014 [16]. Sacubitril/valsartan in dose of 200 mg twice daily was compared with a dose of 10 mg twice daily of enalapril, administered in patients with heart failure, with NYHA class II-IV, with left ventricular ejection fraction of under 40%, with NT-proBNP over 400...
Sacubitril/valsartan reduces biomarkers like troponin and NT-proBNP and increases the levels of cGMP in urine as a result of NEP inhibition [20].

During the study, 1546 of patients died, 711 in sacubitril/valsartan group (558 CV causes) and 833 in the enalapril group (693 CV causes) [9].

The deaths in the context of pump-failure were reduced in the group of sacubitril/valsartan [8].

PARADIGM-HF shown that sacubitril/valsartan is superior in preventing clinical progression of heart failure than enalapril. There is strong evidence that the combination of angiotensin receptor inhibitor and neprilysin is superior to inhibiting RAAS alone in patients with chronic heart failure. Sacubitril/valsartan is strongly recommended to be used for patients with chronic heart failure, left ventricular ejection fraction under 40%, instead of an ACEI or ARB alone. So, the combination was approved with the purpose to reduce the risk of cardiovascular death for patients with chronic heart failure and reduced ejection fraction [17][25].

Sacubitril/valsartan has been included in many other studies.

TITRATION is a double-blind, randomised study, which compare two regimens of up titrating the dose of sacubitril/valsartan. It is a 5 day open-label run-in (sacubitril/valsartan 50 mg twice daily), preceded by 11 weeks double-blind, randomised period (100 mg twice daily for 2 weeks followed by 200 mg twice daily) vs 50 mg twice daily for 2 weeks, 100 mg twice daily for 3 weeks, followed by 200 mg twice daily. In TITRATION study, the purpose was to assess the tolerability of increased dose (from 50 to 200) of sacubitril/valsartan in patients with heart failure [21]. This study compared two regimens of increasing the dose of sacubitril/valsartan, and the results showed an acceptable tolerability [10]. The most common adverse effects were non-serious hypotension and hyperkalaemia, but these not lead to the discontinuation of the treatment. Also, were reported two cases of non-serious angioedema. The tolerability of up titrating dose of sacubitril/valsartan is acceptable [22]. Previously treated patients with ACEI/ARB were tolerated at sacubitril/valsartan target dose. The TITRATION study showed that up titrating dose of sacubitril/valsartan progressively, no serious ad-
verse effects occur and this will increase the therapeutic success [17].

PARAMOUNT is a randomised study, double blind trial, with patients diagnosed with heart failure and preserved ejection fraction. After 12 weeks of treatment, it was observed that the levels of NT-proBNP have decreased. The study evaluated, also, the effect of sacubitril/valsartan on the left atrial structure. After 6 weeks of treatment, left atrial volume was reduced significantly. It was shown that sacubitril/valsartan have positive renal effects, than valsartan alone [23].

PIONEER investigates the effect of sacubitril/valsartan on NT-proBNP. This study will be done in 2018 [24].

PARAGON-HF is a study on patients with heart failure and preserved ejection fraction. Will be completed in 2019 [25].

PARABLE-HF is a study whose purpose is to determine if combination sacubitril/valsartan is safe and to determine the positive effects on the heart and blood vessels in asymptomatic patients, with elevated natriuretic peptide and elevated left atrial volume index, with hypertension, diabetes. Patients will be treated with sacubitril/valsartan for 18 months to evaluate the impact on left ventricular diastolic function [26].

PARASAIL is an interventional study, whose purpose is to describe the tolerability in patients with heart failure with reduced ejection fraction, treated over 6 months with optimal dose of sacubitril/valsartan. This study will describe tolerability, effectiveness and safety of sacubitril/valsartan [27].

TRANSITION study is a randomized study which purpose is to compare in-hospital initiation of sacubitril/valsartan and initiation after hospital discharge in patients with heart failure and reduced ejection fraction who have recently been hospitalised for acute decompensation. This study will be complete in 2018 [28].

Sacubitril/valsartan in guidelines

Sacubitril/valsartan is included in the standard therapy for heart failure as an alternative for ACEI or ARB [23].

Sacubitril/valsartan got recommendations from European Society of Cardiology (ESC) and in American College of Cardiology (ACC) / American Heart Association guidelines (AHA). In ACC/AHA Guideline for the management of Heart Failure (2016), the combination got I-BR which means strong and moderate quality. So, the recommendation is that an ARNI should be used in patients with chronic heart failure [23].

Sacubitril/valsartan has got class IB recommendation in the 2016 ESC Guideline for the Diagnosis and Treatment of Acute and Chronic Heart Failure, which means that is recommended and data derived from one single trial [13]. So, this drug is recommended to replace ACEIs / ARBs in patients with heart failure, to reduce the risk of death in hospitalisation for heart failure [13].

Conclusions

The dual angiotensin-receptor nephrilysin - inhibitor has proven a superior efficacy in decreasing the morbimortality of chronic heart failure patients that the standard of care treatment, and is widely recommended by all the guidelines for treatment in patients with heart failure with reduced ejection fraction, being the first heart failure drug that gets into the guidelines after the completion of only one (but the largest) clinical trial.

Since PARADIGM-HF trial, an increased interest let to the initiation of several other clinical-trial meant to extent the use of ARNI to heart failure patients with preserved ejection fraction and for its early initiation after an acute episode of decompensating HF.

Also there are several issues that await a response regarding the use of ARNI as first-line treatment instead of ACEIS and ARBs, what is the optimal up-titrating strategy, how to use it in patients that are not similar to those enrolled in PARADIGM trial and also about how this drug really works.

Although these questions await responses that for sure will come in the next years, we can neither the less say that ARNI sacubitril-valsartan has the traits of a revolutionary drug that has definitely changed the paradigm of the HF treatment.

References

2. Kobalava Z, Averkov O, Meray L. Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following
short term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP. Eur Heart 32 (Suppl.): 784 – 785
5. McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail. 2011 Sep;13(9):929-36

26. ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLevation (PARABLE). Available at: https://clinicaltrials.gov/ct2/show/NCT02682719
